Browsing Tag
biotechnology
69 posts
Belgium’s Celyad Oncology halts drug research as cash runs thin—will patents be enough?
Celyad Oncology ends R&D to conserve cash and pivot toward IP licensing. Find out why the Belgian biotech is betting on patents to stay afloat.
Skyhawk Therapeutics and Merck sign $2bn RNA drug discovery pact targeting neurological disorders
Skyhawk Therapeutics inks $2B Merck deal to develop RNA-targeted neurology drugs, highlighting splicing modulation as a new frontier.
Maryland Tech Council unveils Rural Technology Network to ignite innovation across underserved regions
Maryland Tech Council launches Rural Technology Network to accelerate innovation, partnerships, and business growth in rural Maryland. Discover how.
Breakthrough for Wilson disease: Innorna’s IN013 wins dual FDA fast-track approvals
Innorna accelerates mRNA treatment for Wilson Disease with dual FDA designations. Discover how IN013 could transform care for rare genetic disorders!
4D Molecular Therapeutics strengthens cash position, eyes Phase 3 success for 4D-150
4D Molecular Therapeutics (4DMT) has announced its full-year 2024 financial results, highlighting key advancements in its late-stage clinical…
AnaptysBio abandons eczema drug after trial failures; shares nosedive
Biotechnology company AnaptysBio, Inc., specializing in innovative autoimmune disease therapies, announced it will halt development of its atopic…
Rallybio Phase 2 trial of RLYB212 begins to tackle FNAIT in high-risk pregnancies
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company known for advancing innovative therapies for rare diseases, has commenced…
Revolutionary anti-aging drug sends Telomir Pharma stock soaring—Is the future of longevity here?
Shares of Telomir Pharmaceuticals, Inc. rose significantly in after-hours trading on Wednesday, regaining lost ground following a promising…
Coya Therapeutics stock surges as investors pump $10m into growth
Coya Therapeutics Inc. (NASDAQ: COYA) witnessed a 9% increase in its share value after securing $10 million through…
Actinogen Medical makes bold A$11.1m move to boost Alzheimer’s drug trial
Actinogen Medical has raised 11.1 million AUD in a significant capital raise led by its CEO, Dr. Steven…